Subscribe
istock-509483224-pills-2
19 April 2018Europe

Sanofi in talks to sell generics unit for €1.9bn

France-based Sanofi has confirmed it is in negotiations to sell its European generics business Zentiva for €1.9 billion ($2.4 billion) to private equity firm Advent International.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
Advent agrees to buy Sanofi’s European generics unit
29 June 2018   Private equity investor Advent International has agreed to acquire France-based Sanofi's European generics business Zentiva.
Big Pharma
Sanofi to acquire Ablynx for €3.9bn
29 January 2018   Biopharmaceutical company Sanofi has revealed plans to acquire biotech firm Ablynx for approximately €3.9 billion ($4.8 billion).
Americas
Sanofi to buy Bioverativ for $11.6bn
23 January 2018   Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Europe
Advent agrees to buy Sanofi’s European generics unit
29 June 2018   Private equity investor Advent International has agreed to acquire France-based Sanofi's European generics business Zentiva.
Big Pharma
Sanofi to acquire Ablynx for €3.9bn
29 January 2018   Biopharmaceutical company Sanofi has revealed plans to acquire biotech firm Ablynx for approximately €3.9 billion ($4.8 billion).
Americas
Sanofi to buy Bioverativ for $11.6bn
23 January 2018   Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.

More on this story

Europe
Advent agrees to buy Sanofi’s European generics unit
29 June 2018   Private equity investor Advent International has agreed to acquire France-based Sanofi's European generics business Zentiva.
Big Pharma
Sanofi to acquire Ablynx for €3.9bn
29 January 2018   Biopharmaceutical company Sanofi has revealed plans to acquire biotech firm Ablynx for approximately €3.9 billion ($4.8 billion).
Americas
Sanofi to buy Bioverativ for $11.6bn
23 January 2018   Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB